World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 000, Number 000, August 2025, pages 000-000


Association Between Platelet-to-Lymphocyte Ratio and Insulin Resistance in Cancer Survivors: A Cross-Sectional Study Based on the NHANES 2005 - 2018

Figures

Figure 1.
Figure 1. Flowchart of the systematic selection process.
Figure 2.
Figure 2. Non-linear association between PLR and IR assessed by HOMR-IR (a), QuICKI (b) and TyG index (c). The solid line represents adjusted ORs, and light blue area represents the 95% CI. The reference point was set at a PLR value of 130.53 across all analyses. All models were adjusted for age, gender, race/ethnicity, marital status, education, family PIR, smoking status, alcohol consumption, sleep duration, physical activity, BMI, history of diabetes status, CVD and hypertension. PLR: platelet-to-lymphocyte ratio; IR: insulin resistance; HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check index; TyG: triglyceride-glucose; PIR: poverty income ratio; BMI: body mass index; CVD: cardiovascular disease; OR: odds ratio; CI: confidence interval.
Figure 3.
Figure 3. Subgroup analysis of the association between PLR and IR assessed by HOMA-IR (a), QUICKI (b), and the TyG index (c). For quartile analysis, odds ratios (ORs) with 95% confidence intervals (CI) represent the comparison of the highest quartile (Q4) versus the lowest quartile (Q1). All OR and interaction measures were adjusted for age, sex, race/ethnicity, marital status, education level, family PIR, smoking status, alcohol use, sleep duration, physical activity, BMI, and comorbidities (CVD and hypertension), with the stratification component in question being excluded. PLR: platelet-to-lymphocyte ratio; IR: insulin resistance; HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check index; TyG: triglyceride-glucose; PIR: poverty income ratio; BMI: body mass index; CVD: cardiovascular disease.
Figure 4.
Figure 4. ROC curve analysis of PLR for predicting IR assessed by HOMA-IR (a), QUICKI (b), and the TyG index (c). PLR: platelet-to-lymphocyte ratio; IR: insulin resistance; HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check index; TyG: triglyceride-glucose; ROC: receiver operating characteristic; AUC: area under the curve.

Tables

Table 1. Characteristics of Study Participants Stratified by Insulin Resistance Indicators
 
CharacteristicsTotal (n = 1,418)HOMA-IRQUICKITyG index
< 2.5 (n = 762)≥ 2.5 (n = 626)P value≥ 0.33 (n = 710)< 0.33 (n = 708)P value< 4.68 (n = 718)≥ 4.68 (n = 700)P value
Non-normally distributed continuous variables are presented as median (Q1, Q3), and categorical variables are reported as n (weighted %). P values are calculated using one-way ANOVA for continuous variables and Chi-square test for categorical variables. PLR: platelet-to-lymphocyte ratio; HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check index; TyG: triglyceride-glucose; PIR: poverty income ratio; PA: physical activity; BMI: body mass index; CVD: cardiovascular disease; ANOVA: analysis of variance.
PLR, median (Q1, Q3)130.5 (101.3, 168.1)125.28 (96.93, 162.97)137.14 (107.03, 173.33)< 0.001123.51 (96.22, 161.42)137.74 (108.22, 174.30)< 0.001126.00 (96.32, 163.28)135.13 (106.39, 172.36)0.002
Age, years, median (Q1, Q3)69.0 (58.0, 78.0)69.00 (57.00, 79.00)68.00 (58.00, 76.00)0.89170.00 (57.75, 79.00)68.00 (58.00, 76.00)0.84968.00 (56.75, 78.00)69.00 (59.25, 78.00)0.004
Gender, n (%)0.0460.0640.222
  Male654 (41.6)296 (39.1)358 (44.3)322 (39.4)332 (44.3)328 (40.1)326 (43.3)
  Female764 (58.4)360 (61.0)404 (55.7)386 (60.6)378 (55.8)372 (59.9)392 (56.7)
Race/ethnicity, n (%)0.0020.0030.253
  Mexican American106 (2.8)32 (1.6)74 (4.1)34 (1.7)72 (4.21)40 (2.3)66 (3.4)
  Other Hispanic98 (2.8)35 (2.6)54 (3.0)35 (2.4)54 (3.2)44 (3.1)45 (2.4)
  Non-Hispanic White964 (85.2)489 (88.8)475 (81.6)533 (88.5)44 (81.4)459 (84.2)505 (86.3)
  Non-Hispanic Black181 (5.3)65 (3.9)116 (6.6)77 (4.2)104 (6.5)119 (6.3)64 (4.1)
  Other race78 (3.9)35 (3.1)43 (4.7)39 (3.2)39 (4.8)40 (4.0)38 (3.8)
Marital status, n (%)0.6560.3070.091
  Never married81 (4.9)37 (5.4)44 (4.4)43 (5.7)38 (4.0)47 (5.4)34 (4.4)
  Married/living with partner892 (68.3)408 (67.5)484 (69.1)441 (67.6)451 (69.1)441 (70.2)451 (66.3)
  Widowed/divorced/separated445 (26.8)211 (27.1)234 (26.5)224 (26.7)221 (27.0)212 (24.4)233 (29.4)
Education, n (%)0.0330.0290.005
  Less than high school301 (12.9)124 (11.0)177 (14.8)133 (11.1)168 (15.0)125 (10.5)176 (15.4)
  Above high school1,117 (87.1)532 (89.0)585 (85.2)575 (88.9)542 (85.0)575 (89.5)542 (84.6)
Family PIR, n (%)< 0.001< 0.001< 0.001
  < 1.3331 (14.7)127 (11.4)204 (18.0)137 (11.6)194 (18.2)143 (12.6)188 (17.0)
  1.3 - 3.5572 (36.1)261 (33.6)311 (38.7)289 (34.6)283 (37.8)276 (31.3)305 (41.2)
  ≥ 3.5515 (49.2)268 (55.1)247 (43.3)282 (53.8)233 (44.0)290 (56.1)225 (41.9)
Smoking status, n (%)0.6970.9560.025
  No663 (48.7)314 (49.3)349 (48.2)334 (48.8)329 (48.7)344 (51.6)319 (45.7)
  Yes755 (51.3)342 (50.8)413 (51.8)374 (51.2)381 (51.3)356 (48.4)399 (54.4)
Alcohol use, n (%)0.001< 0.0010.204
  No354 (20.4)141 (16.9)232 (24.0)150 (16.8)204 (24.6)161 (19.1)193 (21.8)
  Yes1,064 (79.6)515 (83.1)549 (76.0)558 (83.2)506 (75.4)539 (80.9)525 (78.2)
Sleep duration, h/night, n (%)0.0170.0060.042
  < 7428 (27.3)182 (24.6)246 (30.1)194 (24.1)234 (31.1)193 (24.5)235 (30.3)
  7.0 - 9.0793 (60.8)388 (64.4)405 (57.1)418 (64.4)375 (56.5)408 (63.6)385 (57.8)
  ≥ 9197 (11.9)86 (11.0)111 (12.8)96 (11.5)101 (12.4)99 (11.9)98 (11.9)
PA, MET-min/week, n (%)< 0.001< 0.001< 0.001
  < 600698 (43.7)296 (38.5)402 (49.0)319 (38.4)379 (49.9)318 (37.8)380 (50.0)
  ≥ 600720 (56.3)360 (61.5)360 (51.0)389 (61.6)331 (50.1)382 (62.2)338 (50.0)
BMI, kg/m2, n (%)< 0.001< 0.001< 0.001
  < 18.520 (1.8)18 (3.2)2 (0.3)19 (3.2)1 (0.1)17 (3.1)3 (0.4)
  18.5 < 25377 (28.3)292 (45.0)85 (11.1)303 (43.8)74 (10.1)261 (38.6)116 (17.1)
  25 < 30486 (34.1)243 (37.6)243 (30.6)270 (37.9)216 (29.7)231 (33.3)255 (35.0)
  ≥ 30535 (35.8)103 (14.2)432 (58.0)116 (15.2)419 (60.1)191 (25.0)344 (47.5)
Diabetes mellitus, n (%)< 0.001< 0.001< 0.001
  No979 (76.4)559 (90.8)420 (61.6)599 (90.3)380 (60.1)589 (88.3)390 (63.6)
  Yes439 (23.6)97 (9.2)342 (38.4)109 (9.7)330 (39.9)111 (11.7)328 (36.4)
CVD, n (%)< 0.001< 0.0010.002
  No1,066 (80.0)516 (83.8)550 (76.2)559 (83.9)507 (75.5)553 (83.2)513 (76.7)
  Yes352 (20.0)140 (16.2)212 (23.8)149 (16.1)203 (24.5)147 (16.8)205 (23.4)
Hypertension, n (%)< 0.001< 0.001< 0.001
  No596 (48.2)339 (58.4)257 (37.7)363 (58.2)233 (36.4)340 (56.2)256 (39.6)
  Yes822 (51.8)317 (41.6)257 (62.3)345 (41.8)477 (63.6)360 (43.8)462 (60.4)

 

Table 2. The Association Between PLR and Insulin Resistance Stratified by HOMA-IR, QUICKI and TyG Index
 
PLR quartilesBy HOMA-IRBy QUICKIBy TyG index
Model 1Model 2Model 3Model 1Model 2Model 3Model 1Model 2Model 3
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Model 1: non-adjusted model; Model 2: adjusted for age, sex, race/ethnicity, marital status, and family PRI; Model 3: adjusted for Model 1 covariates plus smoking status, alcohol use, sleep duration, physical activity, BMI, CVD and hypertension. PLR: platelet-to-lymphocyte ratio; HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check index; TyG: triglyceride-glucose; BMI: body mass index; CVD: cardiovascular disease; HR: hazard ratio; CI: confidence interval; Ref: reference.
Q1 (< 101.33)RefRefRefRefRefRefRefRefRef
Q2 (101.33 - 130.51)1.19 (0.81, 1.75)0.3751.18 (0.81, 1.73)0.3931.11 (0.75, 1.83)0.4761.22 (0.84, 1.79)0.2981.23 (0.84, 1.79)0.2961.25 (0.81, 1.95)0.3261.57 (1.07, 2.31)0.0211.54 (1.05, 2.28)0.0291.61 (1.05, 2.46)0.027
Q3 (130.51 - 168.18)1.43 (0.96, 2.13)0.0751.37 (0.93, 2.03)0.1111.39 (0.89, 2.15)0.1441.56 (1.05, 2.32)0.0261.51 (1.03, 2.23)0.0371.62 (1.05, 2.51)0.0301.70 (1.15, 2.53)0.0081.65 (1.11, 2.46)0.0131.69 (1.09, 2.62)0.017
Q4 (≥ 168.18)1.64 (1.11, 2.13)0.0131.58 (1.07, 2.35)0.2231.40 (0.90, 2.14)0.1401.80 (1.21, 2.68)0.0031.75 (1.17, 2.60)0.0061.61 (1.02, 2.53)0.0401.67 (1.13, 2.47)0.0101.67 (1.12, 2.49)0.0121.56 (1.02, 2.45)0.035
P for trend1.18 (1.04, 1.34)0.0081.16 (1.03, 1.32)0.0171.13 (0.98, 1.30)0.0911.22 (1.08, 1.39)0.0021.21 (1.06, 1.37)0.0031.19 (1.03, 1.38)0.0211.17 (1.04, 1.33)0.0121.17 (1.03, 1.33)0.0141.15 (1.01, 1.31)0.039

 

Table 3. ROC Curve Analysis of PLR for Predicting Insulin Resistance Assessed by HOMA-IR, QUICKI, and the TyG Index
 
IR indicatorVariableCutoff valueSensitivitySpecificityAUC (95% CI)
HOMA-IRPLR1240.5250.5880.561 (0.531, 0.591)
QUICKIPLR1320.6170.5620.616 (0.587, 0.645)
TyG indexPLR1370.6060.5870.622 (0.593, 0.651)